Dr Jennifer Brown speaks to ecancer about a study she presented at ASH 2022 on zanubrutinib vs ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma.

She explains that patients were randomised between zanubrutinib and ibrutinib and the primary endpoint was overall response rate defined as partial and complete response.

Dr Brown reports that zanubrutinib improves progression free survival compared to ibrutinib with a hazard ratio of 0.65 and a median follow up of 30 months.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

свернуть